JP2016512490A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016512490A5 JP2016512490A5 JP2015559285A JP2015559285A JP2016512490A5 JP 2016512490 A5 JP2016512490 A5 JP 2016512490A5 JP 2015559285 A JP2015559285 A JP 2015559285A JP 2015559285 A JP2015559285 A JP 2015559285A JP 2016512490 A5 JP2016512490 A5 JP 2016512490A5
- Authority
- JP
- Japan
- Prior art keywords
- subject
- pharmaceutical composition
- human igg
- pooled human
- disorder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229940027941 immunoglobulin g Drugs 0.000 claims description 60
- 239000000203 mixture Substances 0.000 claims description 31
- 208000015114 central nervous system disease Diseases 0.000 claims description 22
- 210000003169 central nervous system Anatomy 0.000 claims description 21
- 210000002850 nasal mucosa Anatomy 0.000 claims description 20
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 13
- 208000035475 disorder Diseases 0.000 claims description 13
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 12
- 230000003542 behavioural effect Effects 0.000 claims description 8
- 210000003928 nasal cavity Anatomy 0.000 claims description 8
- 239000004471 Glycine Substances 0.000 claims description 6
- 210000004556 brain Anatomy 0.000 claims description 6
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 6
- 150000001413 amino acids Chemical class 0.000 claims description 5
- 210000001706 olfactory mucosa Anatomy 0.000 claims description 5
- 239000000843 powder Substances 0.000 claims description 5
- 210000003901 trigeminal nerve Anatomy 0.000 claims description 5
- 206010000117 Abnormal behaviour Diseases 0.000 claims description 4
- 208000017194 Affective disease Diseases 0.000 claims description 4
- 208000019022 Mood disease Diseases 0.000 claims description 4
- 230000001717 pathogenic effect Effects 0.000 claims description 4
- 201000000980 schizophrenia Diseases 0.000 claims description 4
- 208000011580 syndromic disease Diseases 0.000 claims description 4
- 208000016192 Demyelinating disease Diseases 0.000 claims description 3
- 208000024827 Alzheimer disease Diseases 0.000 claims description 2
- 206010003694 Atrophy Diseases 0.000 claims description 2
- 208000012239 Developmental disease Diseases 0.000 claims description 2
- 208000027534 Emotional disease Diseases 0.000 claims description 2
- 208000016285 Movement disease Diseases 0.000 claims description 2
- 206010071323 Neuropsychiatric syndrome Diseases 0.000 claims description 2
- 208000025174 PANDAS Diseases 0.000 claims description 2
- 208000021155 Paediatric autoimmune neuropsychiatric disorders associated with streptococcal infection Diseases 0.000 claims description 2
- 206010033799 Paralysis Diseases 0.000 claims description 2
- 208000018737 Parkinson disease Diseases 0.000 claims description 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims description 2
- 206010061372 Streptococcal infection Diseases 0.000 claims description 2
- 230000001154 acute effect Effects 0.000 claims description 2
- 230000037444 atrophy Effects 0.000 claims description 2
- 230000001363 autoimmune Effects 0.000 claims description 2
- 208000018300 basal ganglia disease Diseases 0.000 claims description 2
- 206010015037 epilepsy Diseases 0.000 claims description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 2
- 229940098197 human immunoglobulin g Drugs 0.000 claims description 2
- 230000036651 mood Effects 0.000 claims description 2
- 201000006417 multiple sclerosis Diseases 0.000 claims description 2
- 239000000126 substance Substances 0.000 claims description 2
- 230000009885 systemic effect Effects 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 23
- 210000005036 nerve Anatomy 0.000 claims 2
- 230000000698 schizophrenic effect Effects 0.000 claims 2
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims 1
- 208000027626 Neurocognitive disease Diseases 0.000 claims 1
- 208000027099 Paranoid disease Diseases 0.000 claims 1
- 208000027520 Somatoform disease Diseases 0.000 claims 1
- 208000010934 demyelinating disease of central nervous system Diseases 0.000 claims 1
- 230000002996 emotional effect Effects 0.000 claims 1
- 230000003340 mental effect Effects 0.000 claims 1
- 238000000034 method Methods 0.000 description 79
- 229940122041 Cholinesterase inhibitor Drugs 0.000 description 5
- 230000037396 body weight Effects 0.000 description 5
- 239000000544 cholinesterase inhibitor Substances 0.000 description 5
- 102000018899 Glutamate Receptors Human genes 0.000 description 4
- 108010027915 Glutamate Receptors Proteins 0.000 description 4
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 description 4
- 239000000443 aerosol Substances 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 2
- ADEBPBSSDYVVLD-UHFFFAOYSA-N donepezil Chemical group O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 description 2
- ASUTZQLVASHGKV-JDFRZJQESA-N galanthamine Chemical group O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@@H](O)C=C2 ASUTZQLVASHGKV-JDFRZJQESA-N 0.000 description 2
- BUGYDGFZZOZRHP-UHFFFAOYSA-N memantine Chemical group C1C(C2)CC3(C)CC1(C)CC2(N)C3 BUGYDGFZZOZRHP-UHFFFAOYSA-N 0.000 description 2
- 229960004640 memantine Drugs 0.000 description 2
- 208000020016 psychiatric disease Diseases 0.000 description 2
- 208000024254 Delusional disease Diseases 0.000 description 1
- 208000027776 Extrapyramidal disease Diseases 0.000 description 1
- 206010037779 Radiculopathy Diseases 0.000 description 1
- XSVMFMHYUFZWBK-NSHDSACASA-N Rivastigmine Chemical group CCN(C)C(=O)OC1=CC=CC([C@H](C)N(C)C)=C1 XSVMFMHYUFZWBK-NSHDSACASA-N 0.000 description 1
- 229960003530 donepezil Drugs 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 229960003980 galantamine Drugs 0.000 description 1
- ASUTZQLVASHGKV-UHFFFAOYSA-N galanthamine hydrochloride Natural products O1C(=C23)C(OC)=CC=C2CN(C)CCC23C1CC(O)C=C2 ASUTZQLVASHGKV-UHFFFAOYSA-N 0.000 description 1
- 239000008263 liquid aerosol Substances 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 208000002851 paranoid schizophrenia Diseases 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 229960004136 rivastigmine Drugs 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 229960001685 tacrine Drugs 0.000 description 1
- YLJREFDVOIBQDA-UHFFFAOYSA-N tacrine Chemical group C1=CC=C2C(N)=C(CCCC3)C3=NC2=C1 YLJREFDVOIBQDA-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361769673P | 2013-02-26 | 2013-02-26 | |
| US61/769,673 | 2013-02-26 | ||
| US201361862814P | 2013-08-06 | 2013-08-06 | |
| US61/862,814 | 2013-08-06 | ||
| PCT/US2014/018426 WO2014134070A1 (en) | 2013-02-26 | 2014-02-25 | Treatment of central nervous system disorders by intranasal administration of immunoglobulin g |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016512490A JP2016512490A (ja) | 2016-04-28 |
| JP2016512490A5 true JP2016512490A5 (enExample) | 2017-04-27 |
| JP6379113B2 JP6379113B2 (ja) | 2018-08-22 |
Family
ID=50424697
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015559285A Active JP6379113B2 (ja) | 2013-02-26 | 2014-02-25 | 免疫グロブリンｇの鼻腔内投与による中枢神経系障害の治療 |
Country Status (13)
| Country | Link |
|---|---|
| US (5) | US9556260B2 (enExample) |
| EP (2) | EP3597220A1 (enExample) |
| JP (1) | JP6379113B2 (enExample) |
| AU (2) | AU2014223679B2 (enExample) |
| DK (1) | DK2961426T3 (enExample) |
| ES (1) | ES2759226T3 (enExample) |
| HR (1) | HRP20192111T1 (enExample) |
| HU (1) | HUE046752T2 (enExample) |
| LT (1) | LT2961426T (enExample) |
| PL (1) | PL2961426T3 (enExample) |
| PT (1) | PT2961426T (enExample) |
| SI (1) | SI2961426T1 (enExample) |
| WO (1) | WO2014134070A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20150100042A1 (en) * | 2013-10-07 | 2015-04-09 | Impel Neuropharma Inc. | Muroid Family Nasal Device |
| EP3129013A1 (en) * | 2014-04-10 | 2017-02-15 | Crowley, Patrick | Delivery of non-steroidal antiinflammatory agents to the brain via the nasal tract to treat neurological disorders |
| JP7368856B2 (ja) | 2017-07-25 | 2023-10-25 | トゥルーバインディング，インコーポレイテッド | Ｔｉｍ－３とそのリガンドとの相互作用の遮断によるがん治療 |
| JP7334145B2 (ja) | 2017-08-20 | 2023-08-28 | ネイサス ファーマ リミテッド | 鼻腔内送達用乾燥粉末組成物 |
| US11844859B2 (en) | 2017-08-20 | 2023-12-19 | Nasus Pharma Ltd. | Dry powder compositions for intranasal delivery |
| CN116063505B (zh) | 2019-01-30 | 2024-05-03 | 真和制药有限公司 | 抗gal3抗体及其用途 |
| WO2020163815A1 (en) * | 2019-02-07 | 2020-08-13 | Innomed Technologies, Inc. | Ivig treatments for bell's palsy |
| WO2020263484A1 (en) * | 2019-06-28 | 2020-12-30 | Mayo Foundation For Medical Education And Research | Methods and materials for treating neuromyelitis optica spectrum diseases |
| JP2022544414A (ja) * | 2019-08-13 | 2022-10-18 | アルティミューン インコーポレーティッド | 治療剤の有効性及びその投与の経路 |
| US12281166B2 (en) | 2020-05-26 | 2025-04-22 | Truebinding, Inc. | Methods of treating inflammatory diseases by blocking Galectin-3 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE348942B (enExample) | 1970-06-02 | 1972-09-18 | Statens Bakteriologiska Labor | |
| US5624898A (en) | 1989-12-05 | 1997-04-29 | Ramsey Foundation | Method for administering neurologic agents to the brain |
| KR100390480B1 (ko) | 1995-01-23 | 2003-10-04 | 디렉트-할러 아/에스 | 흡입기 |
| KR100692422B1 (ko) | 1999-03-03 | 2007-03-09 | 옵티노즈 에이에스 | 코 내부로 물질을 전달하는 장치 |
| US6585957B1 (en) | 2000-01-25 | 2003-07-01 | Aeropharm Technology Incorporated | Medicinal aerosol formulation |
| US20070254889A1 (en) * | 2001-04-23 | 2007-11-01 | Lee-Way Jin | Compounds and methods useful for rescuing cells from beta-amyloid toxicity and treatment of Alzheimer's disease |
| MXPA04003156A (es) | 2001-10-04 | 2005-01-25 | Protein Therapeutics Inc | El uso de gammaglobulina para el tratamiento de enfermedades mediadas inmunes . |
| US20040101909A1 (en) | 2002-08-20 | 2004-05-27 | Hema-Quebec, 2535 Boul. Laurier, Ste-Foy, Quebec, Canada G1V 4M3 | Purification of polyreactive autoantibodies and uses thereof |
| US20090136505A1 (en) | 2005-02-23 | 2009-05-28 | Johanna Bentz | Intranasal Administration of Active Agents to the Central Nervous System |
| CN101184499B (zh) | 2005-02-23 | 2012-03-28 | 阿尔扎公司 | 活性剂向中枢神经系统的鼻内施用 |
| WO2007074880A1 (ja) * | 2005-12-28 | 2007-07-05 | Chugai Seiyaku Kabushiki Kaisha | 抗体含有安定化製剤 |
| PT1981540E (pt) | 2006-01-30 | 2013-05-07 | Grifols Therapeutics Inc | Método de tratamento e profilaxia de doenças relacionadas com a deposição de amilóides utilizando igm |
| CN101410134A (zh) * | 2006-02-15 | 2009-04-15 | 台拉维夫大学拉莫特 | 展示蛋白质a作为向脑部递送的抗体和免疫复合物的结合剂的丝状噬菌体 |
| WO2008154337A1 (en) | 2007-06-08 | 2008-12-18 | Healthpartners Research Foundation | Pharmaceutical compositions and methods for enhancing targeting of therapeutic compounds to the central nervous system |
| EP2257804B1 (en) * | 2008-02-29 | 2013-12-11 | Baxter International Inc. | Anti-amyloid activity of intravenous immunoglobulin (ivig) in vitro |
| US8622993B2 (en) | 2009-12-18 | 2014-01-07 | Healthpartners Research Foundation | Device and method for delivering therapeutic substances to the maxillary sinus of a patient |
| TR201903403T4 (tr) * | 2010-02-04 | 2019-04-22 | Csl Behring Ag | İmmünoglobulin preparatı. |
| WO2011150284A2 (en) * | 2010-05-26 | 2011-12-01 | Baxter International Inc. | Removal of serine proteases by treatment with finely divided silicon dioxide |
-
2014
- 2014-02-25 PT PT147148159T patent/PT2961426T/pt unknown
- 2014-02-25 HU HUE14714815A patent/HUE046752T2/hu unknown
- 2014-02-25 HR HRP20192111TT patent/HRP20192111T1/hr unknown
- 2014-02-25 PL PL14714815T patent/PL2961426T3/pl unknown
- 2014-02-25 AU AU2014223679A patent/AU2014223679B2/en active Active
- 2014-02-25 US US14/189,981 patent/US9556260B2/en active Active
- 2014-02-25 JP JP2015559285A patent/JP6379113B2/ja active Active
- 2014-02-25 ES ES14714815T patent/ES2759226T3/es active Active
- 2014-02-25 LT LTEP14714815.9T patent/LT2961426T/lt unknown
- 2014-02-25 DK DK14714815T patent/DK2961426T3/da active
- 2014-02-25 SI SI201431417T patent/SI2961426T1/sl unknown
- 2014-02-25 EP EP19197257.9A patent/EP3597220A1/en not_active Withdrawn
- 2014-02-25 EP EP14714815.9A patent/EP2961426B1/en active Active
- 2014-02-25 WO PCT/US2014/018426 patent/WO2014134070A1/en not_active Ceased
-
2016
- 2016-10-26 US US15/335,027 patent/US10144776B2/en active Active
-
2018
- 2018-10-19 US US16/165,993 patent/US20190055307A1/en not_active Abandoned
- 2018-11-08 AU AU2018260883A patent/AU2018260883B2/en not_active Expired - Fee Related
-
2020
- 2020-12-14 US US17/121,553 patent/US11851481B2/en active Active
-
2023
- 2023-11-13 US US18/507,265 patent/US12503501B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016512490A5 (enExample) | ||
| HRP20192111T1 (hr) | Liječenje poremećaja središnjeg živčanog sustava intranazalnom primjenom imunoglobulina g | |
| US10828266B2 (en) | Topical regional neuro-affective therapy with caryophyllene | |
| BR112013022249B8 (pt) | Dispositivo de distribuição de droga nasal | |
| MX2016008138A (es) | Sistema para el suministro transdermico de ingredientes activos. | |
| MX2020012077A (es) | Composiciones y metodos para el tratamiento de la enfermedad de parkinson. | |
| JP2015524423A5 (enExample) | ||
| JP2017531044A5 (enExample) | ||
| ATE457985T1 (de) | Substituierte pyrazinonderivate zur verwendung als arzneimittel | |
| IL318427A (en) | Varenicline compound for use as a medication for treating dry eye, increasing tear production and treating eye discomfort and a pramipexole preparation containing varenicline | |
| IL181247A0 (en) | Composition and method for improved bioavailability and enhanced brain delivery of 5,5-diphenyl barbituric acid | |
| BR112021013244A8 (pt) | Dispositivo de entrega de fármaco nasal | |
| Khatoon et al. | The role of natural products in Alzheimer's and Parkinson's disease | |
| ZA202201445B (en) | Olfactory delivery of therapeutic compounds to the central nervous system | |
| TW200509985A (en) | Drug delivery system for sub-Tenon administration of fine particles | |
| IL194346A0 (en) | Peptide substance stimulating regeneration of central nervous system neurons, pharmaceutical composition on its base, and the method of its application | |
| EA200870452A1 (ru) | Производные замещенного пиразинона для применения в качестве лекарственных средств | |
| JP7062804B2 (ja) | レビー小体病の治療および／または予防剤 | |
| ZA202200335B (en) | Pharmaceutical composition of temozolomide. | |
| JPWO2021127541A5 (enExample) | ||
| US11541004B2 (en) | Method for treating or mitigating Parkinson's disease using nicotine inhaler or nicotine nasal spray | |
| DE602007004018D1 (de) | Imidazolcarbonsäurealkylester-haltiges Medikament zur Behandlung neurodegenerativer Erkrankungen | |
| EA201590323A1 (ru) | Способ введения активных веществ в головной мозг | |
| RU2023127460A (ru) | Фармацевтическая композиция для профилактики и/или лечения атопического дерматита, включающая антагонист ил-31 в качестве активного ингредиента | |
| UA111462C2 (uk) | Застосування (s)-2,6-діаміногексанової кислоти 3-метил-1,2,4-триазоліл-5-тіоацетату як активної основи лікарських засобів для профілактики та лікування порушень життєзабезпечуючих функцій цнс при важких формах гострого отруєння етанолом |